AZD7762

Catalog No.S1532

Molecular Weight(MW): 362.42

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Cited by 55 Publications

Cancer Cell, 2019, 35(6):851-867

PubMed: 31185210 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Discov, 2012, 2(6):524-39

PubMed: 22628408 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(6):542-6

PubMed: 21623355 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(6):1032-1045

PubMed: 30771522 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(7):2290-2304

PubMed: 30538111 ( click the link to review the publication )

Br J Pharmacol, 2019, 10.1111/bph.14916

PubMed: 31670839 ( click the link to review the publication )

Cancers (Basel), 2019, 11(8)

PubMed: 31362447 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0290

PubMed: 31871265 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):762-770

PubMed: 30872379 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163.MCT-19-0474

PubMed: 31597711 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(10):1985-1998

PubMed: 31300540 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:195

PubMed: 31372095 ( click the link to review the publication )

Cell Cycle, 2019, 18(8):834-847

PubMed: 30943845 ( click the link to review the publication )

Oncotarget, 2019, 10(62):6691-6712

PubMed: 31803363 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(10):5029-5049

PubMed: 29596642 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1629-1643

PubMed: 29326282 ( click the link to review the publication )

Diabetes, 2018, 67(11):2319-2328

PubMed: 30104248 ( click the link to review the publication )

Cancer Lett, 2018, 431:142-149

PubMed: 29859297 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(7):612-618

PubMed: 29897742 ( click the link to review the publication )
Nat Commun, 2017, 8(1):1392

PubMed: 29123096 ( click the link to review the publication )

Haematologica, 2017, 102(5):826-834

PubMed: 28154085 ( click the link to review the publication )

Cancer Lett, 2017, 392:71-82

PubMed: 28126323 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):1

PubMed: 28049532 ( click the link to review the publication )

Eur J Pharm Sci, 2017, 109:223-232

PubMed: 28822757 ( click the link to review the publication )

Oncotarget, 2017, 8(7):10966-10979

PubMed: 28030798 ( click the link to review the publication )

Cancer Res, 2016, 76(11):3319-31

PubMed: 26988986 ( click the link to review the publication )

Oncogene, 2016, 35(36):4689-97

PubMed: 26804177 ( click the link to review the publication )

PLoS Pathog, 2016, 12(2):e1005424

PubMed: 26891221 ( click the link to review the publication )

Mol Cancer Res, 2016, 14(5):437-47

PubMed: 26979711 ( click the link to review the publication )

J Biol Chem, 2016, 291(17):9330-42

PubMed: 26940878 ( click the link to review the publication )

Anticancer Res, 2016, 36(6):2649-57

PubMed: 27272773 ( click the link to review the publication )

J Pathol, 2015, 10.1002/path.4528

PubMed: 25757065 ( click the link to review the publication )

Biochem Pharmacol, 2015, 93(2):210-20

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15:462

PubMed: 26054341 ( click the link to review the publication )

Oncotarget, 2015, 6(35):37229-40

PubMed: 26439697 ( click the link to review the publication )

Oncotarget, 2015, 6(25):21074-84

PubMed: 26025928 ( click the link to review the publication )

Cell Rep, 2014, 10.1016/j.celrep.2014.10.024

PubMed: ( click the link to review the publication )

Cell Rep, 2014, 9(4):1375-86

PubMed: 25456132 ( click the link to review the publication )

Sci Signal, 2014, 7(326):ra47

PubMed: 24847116 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1223

PubMed: 24810059 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1253

PubMed: 24853431 ( click the link to review the publication )

Int J Oncol, 2014, 45(3):1159-66

PubMed: 24969815 ( click the link to review the publication )

Int J Gynecol Cancer, 2014, 24(5):838-43

PubMed: 24804869 ( click the link to review the publication )
Oncotarget, 2014, 5(21):10546-57

PubMed: 25301733 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

J Cell Mol Med, 2013, 18(1):143-55

PubMed: 24238094 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55493

PubMed: 23405159 ( click the link to review the publication )

Cancer Biol Ther, 2012, 13(6):379-88

PubMed: 22313687 ( click the link to review the publication )

Cancer Biol Ther, 2011, 12(3):215-28

PubMed: 21642769 ( click the link to review the publication )

PLoS One, 2010, 5(12):e14335

PubMed: 21179472 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Description

AZD7762 is a potent and selective inhibitor of Chk1 with IC50 of 5 nM in a cell-free assay. It is equally potent against Chk2 and less potent against CAM, Yes, Fyn, Lyn, Hck and Lck. Phase 1.

Targets

Chk1 ^[1] (Cell-free assay)	Chk2 ^[1] (Cell-free assay)
5 nM	<10 nM

In vitro

AZD7762, a more selective Chk1 inhibitor, inhibits Chk1 phosphorylation of a cdc25C peptide by reversibly binding to the ATP-binding site of Chk1, with IC50 of 5 nM and K_i of 3.6 nM. AZD7762 induces cell arrest with EC50 of 0.620 μM, and significantly abrogates the camptothecin induced G2 arrest with an EC50 of 10 nM, by blocking the chk1 dependent degradation of Cdc25A and activation of Cyclin A. AZD7762 (300 nM) enhances the antitumor efficacy of gemcitabine against SW620 and topotecan against MDA-MB-231 by reducing the GI50 values from 24.1 nM and 2.25 μM to 1.08 nM and 0.15 μM, respectively. ^[1] AZD7762 shows cytotoxicity against a variety of neuroblastoma cell lines bearing p53 wild type, p53 mutation, Mdm2 amplification or p14 deletion with IC50 values ranging from 82.6-505.9 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KASUMI-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXfaT4JVUUN3ME2wMlAxODJ\|NDFOwG0>	NH\1eGZUSU6JRWK=
NKM-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M360NmlEPTB;MD6wNFA1OTVizszN	MX7TRW5ITVJ?
MV-4-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTBwMECwOFI2KM7:TR?=	NEnvUWRUSU6JRWK=
NCI-H1703	NXzOSVBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVzJR\|UxRTBwMEC2OFMh\|ryP	NU[0SZFvW0GQR1XS
A204	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXLoVnZoUUN3ME2wMlAxQDV4IN88US=>	NETRVHVUSU6JRWK=
CGTH-W-1	NVXrfYlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwMEG0NkDPxE1?	M4[5[XNCVkeHUh?=
MLMA	MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTBwMEK4OFkh\|ryP	M4HnZXNCVkeHUh?=
GOTO	MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfkUXVKSzVyPUCuNFMyOiEQvF2=	NEPvUIFUSU6JRWK=
KE-37	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\hOJhKSzVyPUCuNFMyPDJizszN	MkXXV2FPT0WU
ES4	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3KTWM2OD1yLkCzNlUyKM7:TR?=	MUTTRW5ITVJ?
ATN-1	NG\1WWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHmwNZhKSzVyPUCuNFM1OTdizszN	M3[4bXNCVkeHUh?=
MHH-PREB-1	MkC0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV[w[ZkzUUN3ME2wMlA{PDR{IN88US=>	MXnTRW5ITVJ?
SW756	M4T4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTBwMEO1O\|kh\|ryP	MWPTRW5ITVJ?
CTV-1	MlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH33PIVKSzVyPUCuNFM5QTZizszN	NH\DUVJUSU6JRWK=
HCC1806	NHT6Z5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33COWlEPTB;MD6wOFAzOiEQvF2=	NG[0PIFUSU6JRWK=
NEC8	NWrUXXd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1qzN2lEPTB;MD6wOFIxOyEQvF2=	NHPxWGNUSU6JRWK=
P12-ICHIKAWA	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnjKTWM2OD1yLkC0N\|E3KM7:TR?=	M3zNc3NCVkeHUh?=
DEL	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXXTWM2OD1yLkC0OVkzKM7:TR?=	NYHSdnFWW0GQR1XS
KM12	NHTKSoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NImyc3dKSzVyPUCuNFUyPThizszN	NGHrUllUSU6JRWK=
LB1047-RCC	M3XtXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2r0O2lEPTB;MD6wOlAzPSEQvF2=	Ml;TV2FPT0WU
LB2241-RCC	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTBwME[xNFIh\|ryP	MWLTRW5ITVJ?
NOMO-1	NWLrd3BQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPGOndKSzVyPUCuNFYyOTVizszN	MWXTRW5ITVJ?
NB14	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjJO3JKSzVyPUCuNFYyOzZizszN	NFjv[4dUSU6JRWK=
ONS-76	MlPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwME[xPVYh\|ryP	M1LrcHNCVkeHUh?=
HD-MY-Z	MoHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwME[yOVUh\|ryP	M{fFVnNCVkeHUh?=
G-402	NIPWNXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlj0TWM2OD1yLkC2OFYh\|ryP	MX;TRW5ITVJ?
ES1	M3S1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTBwMEexOFYh\|ryP	NGrF[3dUSU6JRWK=
L-363	NVTFbGNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHNd3d[UUN3ME2wMlA4OzlizszN	MXnTRW5ITVJ?
A4-Fuk	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mln4TWM2OD1yLkC3OFg3KM7:TR?=	NXrhd\|F3W0GQR1XS
OC-314	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMEe4NFch\|ryP	NH\mOXdUSU6JRWK=
SK-LU-1	Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4W2SWlEPTB;MD6wPFQzOSEQvF2=	M3S2T3NCVkeHUh?=
MDA-MB-157	NGLXWlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{G5WWlEPTB;MD6wPFY2QSEQvF2=	MoO3V2FPT0WU
HuP-T3	MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMEi3NUDPxE1?	NFXudYpUSU6JRWK=
A3-KAW	NEDJTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vEfGlEPTB;MD6wPFgxPiEQvF2=	MVTTRW5ITVJ?
MOLT-16	NIG5UGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIr6OoNKSzVyPUCuNFg5ODdizszN	M3f1WHNCVkeHUh?=
COLO-679	M4XTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLwR4FIUUN3ME2wMlA6ODlzIN88US=>	MlvSV2FPT0WU
EM-2	NUDzWHFoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfBboFiUUN3ME2wMlA6QTB\|IN88US=>	NFywZ4hUSU6JRWK=
ES8	NYTrZodpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTBwMEm5NVgh\|ryP	MkmxV2FPT0WU
SK-MEL-2	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwMUCwN\|Mh\|ryP	MnS0V2FPT0WU
ES3	NUKxdHpKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGjTRmhKSzVyPUCuNVAzKM7:TR?=	MUTTRW5ITVJ?
HSC-4	NUDjSo9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofUTWM2OD1yLkGwOVU1KM7:TR?=	M1X5dXNCVkeHUh?=
697	NH7hZ4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXtTWM2OD1yLkGxNFY{KM7:TR?=	MnPsV2FPT0WU
TGBC11TKB	NYDCNGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\DRlR4UUN3ME2wMlEyODl\|IN88US=>	M1fDcHNCVkeHUh?=
SK-PN-DW	Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXHU45KSzVyPUCuNVE5PiEQvF2=	M3XqbnNCVkeHUh?=
H9	MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzPTWM2OD1yLkGyNVY2KM7:TR?=	NXXYV2t3W0GQR1XS
NCI-H2122	Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrKTWM2OD1yLkGyNlUh\|ryP	NID4WGpUSU6JRWK=
ML-2	M3PPOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlf0TWM2OD1yLkGyOFg1KM7:TR?=	NH\jSWpUSU6JRWK=
MC-IXC	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\IS4FWUUN3ME2wMlEzQDR\|IN88US=>	Ml\CV2FPT0WU
KYSE-140	M4Gybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMUOwOFEh\|ryP	M1viPXNCVkeHUh?=
DOHH-2	NIXJSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jZTGlEPTB;MD6xN\|A3PCEQvF2=	MnXWV2FPT0WU
MEL-JUSO	M3PX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTBwMUOxNlgh\|ryP	MWHTRW5ITVJ?
P30-OHK	M3Lr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjIe5Z5UUN3ME2wMlE{OTZizszN	M3qwUHNCVkeHUh?=
CTB-1	Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkO0TWM2OD1yLkGzN\|I2KM7:TR?=	NWTTdZVrW0GQR1XS
ACHN	M4PvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWnlTow2UUN3ME2wMlE{OzZ7IN88US=>	NVHSV2pHW0GQR1XS
ES5	NULyPYE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4jkfmlEPTB;MD6xN\|Q4PiEQvF2=	MVHTRW5ITVJ?
SF539	NUTvTnRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zmO2lEPTB;MD6xN\|Y5KM7:TR?=	MorIV2FPT0WU
D-283MED	NXLRbXRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnG2TWM2OD1yLkGzOlg4KM7:TR?=	NIrJXoFUSU6JRWK=
OVCAR-5	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2C1[GlEPTB;MD6xN\|g6PCEQvF2=	NFfBW\|NUSU6JRWK=
RPMI-8866	MnPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInxR4ZKSzVyPUCuNVM6OjVizszN	MYLTRW5ITVJ?
PANC-03-27	M3\Bfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofTTWM2OD1yLkG0Nlg5KM7:TR?=	NYKyOlhuW0GQR1XS
M14	NF7iNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P5bWlEPTB;MD6xOFQ3OyEQvF2=	NVS1TphGW0GQR1XS
D-566MG	M3;jb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvmNJl[UUN3ME2wMlE1PjlizszN	NIfBVIlUSU6JRWK=
Ramos-2G6-4C10	M3vvW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwMUS4OFIh\|ryP	M4rBS3NCVkeHUh?=
NOS-1	NGTQVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwMUS5Olch\|ryP	MlLOV2FPT0WU
YH-13	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\jRoRKSzVyPUCuNVU3PzRizszN	M1PDXXNCVkeHUh?=
NB17	NEnvXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfVTWM2OD1yLkG1O\|g3KM7:TR?=	NH\PXWFUSU6JRWK=
U-2-OS	NWHpOZdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HBUWlEPTB;MD6xOVg1PyEQvF2=	Mn\nV2FPT0WU
ES7	NFP1UlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVn6V5B{UUN3ME2wMlE3ODFzIN88US=>	M4DPR3NCVkeHUh?=
LoVo	M4nwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7sOIRKSzVyPUCuNVYyPjZizszN	M1PoNXNCVkeHUh?=
QIMR-WIL	NXnlcHhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1y5V2lEPTB;MD6xOlMyOSEQvF2=	MWHTRW5ITVJ?
ESS-1	M2LRZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\OU3NmUUN3ME2wMlE3PDF\|IN88US=>	Mn\TV2FPT0WU
LAMA-84	MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NE\4bmZKSzVyPUCuNVY2ODNizszN	M{DteXNCVkeHUh?=
TGBC24TKB	NELDfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHVbVFKSzVyPUCuNVY2OzVizszN	Mnz4V2FPT0WU
KU812	NWXuN2ZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rF[GlEPTB;MD6xOlg{KM7:TR?=	NVjqOI01W0GQR1XS
KARPAS-45	NE[zeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMU[4OFch\|ryP	MkfyV2FPT0WU
ACN	Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV:1UHJRUUN3ME2wMlE4OTdzIN88US=>	MmKxV2FPT0WU
RPMI-8226	MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHpVItKSzVyPUCuNVc1PjRizszN	M4\RdHNCVkeHUh?=
GR-ST	MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXSUnRSUUN3ME2wMlE4QDJ5IN88US=>	NFvGNo9USU6JRWK=
SK-UT-1	MkDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XEXWlEPTB;MD6xPFU6QSEQvF2=	M2TPcXNCVkeHUh?=
SK-N-AS	NVr1bFBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoD1TWM2OD1yLkG4PFE2KM7:TR?=	M3\vVnNCVkeHUh?=
EW-1	MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXDcJlFUUN3ME2wMlE5QTB3IN88US=>	M2TjUnNCVkeHUh?=
5637	NF35ZW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULFVGpbUUN3ME2wMlE6Ojd6IN88US=>	NUDRVJpPW0GQR1XS
GI-1	M{jzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\LZ3BKSzVyPUCuNVk2PjFizszN	NFmyUZpUSU6JRWK=
NCI-H1395	NFTJ[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYKxW2JSUUN3ME2wMlE6PzZzIN88US=>	NUnPcXhLW0GQR1XS
CHP-212	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vkZWlEPTB;MD6xPVc5OiEQvF2=	NXPvdIkyW0GQR1XS
A427	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPWTXh[UUN3ME2wMlE6QDN{IN88US=>	NGrE[FJUSU6JRWK=
BE-13	NHXVXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7nSnozUUN3ME2wMlIxOTF5IN88US=>	MX;TRW5ITVJ?
RS4-11	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwMkCzNVgh\|ryP	Mn\3V2FPT0WU
TI-73	M{LVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnr3TWM2OD1yLkKwPFc{KM7:TR?=	NFi4d25USU6JRWK=
HAL-01	NITrfYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXlTWM2OD1yLkKwPVch\|ryP	MX\TRW5ITVJ?
KY821	NXPhcVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojsTWM2OD1yLkKxOFI6KM7:TR?=	M37CTnNCVkeHUh?=
H4	NUT3O2FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fXOmlEPTB;MD6yNlA3OiEQvF2=	NGXsfllUSU6JRWK=
EPLC-272H	M4XkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrtcYFKSzVyPUCuNlIxPjhizszN	NIPj[pdUSU6JRWK=
COR-L105	NEe3VmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTBwMkKyN\|Uh\|ryP	M1ez[XNCVkeHUh?=
769-P	M4\PfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF21e5FKSzVyPUCuNlIzQThizszN	NFrDSpJUSU6JRWK=
HEL	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfmdnBKSzVyPUCuNlI1PTRizszN	M2fsO3NCVkeHUh?=
VA-ES-BJ	NVTNUIJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXJN\|BKSzVyPUCuNlI2PTdizszN	MUDTRW5ITVJ?
IST-MEL1	Mn;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2nVRWlEPTB;MD6yNlU4KM7:TR?=	NX\GPGw2W0GQR1XS
KYSE-270	M{G4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDze3NKSzVyPUCuNlI3OzNizszN	NIjWOI5USU6JRWK=
RH-1	NHHS[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3kNXFKSzVyPUCuNlI3PjZizszN	MnHIV2FPT0WU
JVM-3	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHoSnhKSzVyPUCuNlMxOzZizszN	NXnMfmRmW0GQR1XS
RPMI-7951	NIS5fo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMkOwOVYh\|ryP	Mm[zV2FPT0WU
JAR	MnXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTBwMkOyN\|gh\|ryP	MljHV2FPT0WU
MOLT-4	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMkO4OUDPxE1?	NI\rV4pUSU6JRWK=
ALL-PO	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPVTWM2OD1yLkK0NlQ{KM7:TR?=	M4DpUHNCVkeHUh?=
SNU-387	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXW3PJZzUUN3ME2wMlI1OzN7IN88US=>	MoHpV2FPT0WU
IGROV-1	NVXL[pMxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwMkS0NFEh\|ryP	NUO2dllOW0GQR1XS
MPP-89	NGjyVJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHSxfI5KSzVyPUCuNlQ1PTFizszN	M{PyO3NCVkeHUh?=
T98G	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHeyeGlKSzVyPUCuNlQ2PjhizszN	MnrGV2FPT0WU
NCI-H510A	NHKzR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3;HSGlEPTB;MD6yOFYzPiEQvF2=	M4DmcnNCVkeHUh?=
KOSC-2	MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfVTWM2OD1yLkK0OlcyKM7:TR?=	NFHwUo5USU6JRWK=
NCI-H23	MkjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\LcGlEPTB;MD6yOFc3OSEQvF2=	M3K3fXNCVkeHUh?=
MC116	M{nXXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HzRmlEPTB;MD6yOVY2PCEQvF2=	M1HQc3NCVkeHUh?=
8-MG-BA	NHm0NIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonwTWM2OD1yLkK1O\|Y5KM7:TR?=	M2\MWnNCVkeHUh?=
ABC-1	M3;NSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITVNWdKSzVyPUCuNlYxPjRizszN	NEXXUpBUSU6JRWK=
J-RT3-T3-5	NWX0RWxNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMk[2O\|gh\|ryP	MWPTRW5ITVJ?
NCI-SNU-1	M3vYWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMkewOVkh\|ryP	M1iwSXNCVkeHUh?=
HCC1395	MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPIZ3REUUN3ME2wMlI4ODh7IN88US=>	NF;hO4pUSU6JRWK=
BB65-RCC	NXLrdmZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHK1V5RKSzVyPUCuNlcxQTdizszN	MnXEV2FPT0WU
NCI-H1755	M{HFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwMkezNFQh\|ryP	NUHqfGwyW0GQR1XS
OVCAR-3	NIjnb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXWTWM2OD1yLkK3N\|g2KM7:TR?=	MorTV2FPT0WU
MKN45	MoLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF7JdXFKSzVyPUCuNlc6QCEQvF2=	M1fyTnNCVkeHUh?=
TYK-nu	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTBwMkiwOkDPxE1?	NUX2eIhbW0GQR1XS
SNU-C2B	NInmWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1L0SWlEPTB;MD6yPFE{PCEQvF2=	M37vTnNCVkeHUh?=
H-EMC-SS	M4T6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHGzO3lKSzVyPUCuNlg{PTRizszN	NEfrSZBUSU6JRWK=
CAKI-1	NFnkSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nIbWlEPTB;MD6yPFY5KM7:TR?=	M1XOOXNCVkeHUh?=
EW-24	M17QOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTwc3JKSzVyPUCuNlg6OSEQvF2=	NUL6ZY5KW0GQR1XS
RXF393	NYj4VWlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnWZXRKSzVyPUCuNlkxODhizszN	NH7ybnNUSU6JRWK=
CCRF-CEM	M3G5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3Sd4JKSzVyPUCuNlkyPTRizszN	M3TZdXNCVkeHUh?=
HOP-92	NFzqWVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHznW3FKSzVyPUCuNlkzPzlizszN	NHvOUWVUSU6JRWK=
COLO-684	Mle3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVHRb4NJUUN3ME2wMlI6PDB4IN88US=>	MWLTRW5ITVJ?
NCI-H28	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPmSJdxUUN3ME2wMlI6PzB2IN88US=>	NUC4TG1FW0GQR1XS
HuO9	Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7nTWM2OD1yLkK5O\|k{KM7:TR?=	MV\TRW5ITVJ?
SF295	NGLW[nRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mly3TWM2OD1yLkK5PFAzKM7:TR?=	Mn;CV2FPT0WU
COLO-829	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY\0eGI{UUN3ME2wMlI6QDR3IN88US=>	M122O3NCVkeHUh?=
MSTO-211H	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\5ZmlEPTB;MD6yPVg2PSEQvF2=	MofXV2FPT0WU
MDA-MB-361	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLoTnBZUUN3ME2wMlI6QDl4IN88US=>	NGHjd\|RUSU6JRWK=
FTC-133	M2i2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M174S2lEPTB;MD6zNFI3PSEQvF2=	MV3TRW5ITVJ?
Mewo	NXqxd3g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIH4N2lKSzVyPUCuN\|A1OzFizszN	NV\RUo1nW0GQR1XS
HCC70	Ml3US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnzCTWM2OD1yLkOwOlY2KM7:TR?=	NED6ZWJUSU6JRWK=
BB30-HNC	NIXtco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwM{G1NlUh\|ryP	MVHTRW5ITVJ?
LCLC-97TM1	NEnxT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnpcHpIUUN3ME2wMlMyPTZ4IN88US=>	NYDZXJZWW0GQR1XS
HCC2998	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX\K[4lqUUN3ME2wMlMyPjVizszN	MWHTRW5ITVJ?
NBsusSR	MljUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fybmlEPTB;MD6zNVgyQSEQvF2=	M1T4e3NCVkeHUh?=
OVCAR-4	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrpfWVzUUN3ME2wMlMzODJzIN88US=>	NIm0dXVUSU6JRWK=
NCI-H209	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MonpTWM2OD1yLkOyN\|U{KM7:TR?=	NGHqd5FUSU6JRWK=
ChaGo-K-1	NXzHNplYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHlO5dKSzVyPUCuN\|I1QDlizszN	Ml;nV2FPT0WU
KALS-1	NHPp[2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jlV2lEPTB;MD6zNlU6PCEQvF2=	MVPTRW5ITVJ?
D-423MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXH6N\|JsUUN3ME2wMlM{OTR{IN88US=>	NW[0W3pbW0GQR1XS
Detroit562	NF7NbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfoTWM2OD1yLkOzN\|Q{KM7:TR?=	NWXaOVhQW0GQR1XS
HT-144	Mlf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PlPWlEPTB;MD6zN\|gyKM7:TR?=	MVLTRW5ITVJ?
MEG-01	MorOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITS[JpKSzVyPUCuN\|Q2QDRizszN	MVPTRW5ITVJ?
BV-173	NXPYcmJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{SybGlEPTB;MD6zOFU6PiEQvF2=	NH3Qe2RUSU6JRWK=
MZ7-mel	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGCwNGFKSzVyPUCuN\|Q3PzdizszN	MofoV2FPT0WU
C32	M4\3UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3raPGlEPTB;MD6zOFY5OiEQvF2=	MWHTRW5ITVJ?
DU-4475	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3;ENWlEPTB;MD6zOFg4PSEQvF2=	NIfpZVlUSU6JRWK=
KP-N-YN	M{fmO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjUT3JxUUN3ME2wMlM1QDh5IN88US=>	M2LSTHNCVkeHUh?=
MKN1	NUnBOGRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmDFTWM2OD1yLkO1NFAzKM7:TR?=	M3y2U3NCVkeHUh?=
8505C	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmP6TWM2OD1yLkO1NFAzKM7:TR?=	MkHBV2FPT0WU
OVCAR-8	MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDTeWhKSzVyPUCuN\|U2QDRizszN	MVPTRW5ITVJ?
NH-12	NYfIcZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkD4TWM2OD1yLkO1Olk3KM7:TR?=	MWHTRW5ITVJ?
COR-L88	NIrvc2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwM{[0PFIh\|ryP	Mnm1V2FPT0WU
T-24	NV3RdVJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTBwM{[5PFUh\|ryP	M1K2N3NCVkeHUh?=
MIA-PaCa-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\iTWM2OD1yLkO3OFk4KM7:TR?=	NIXKXJFUSU6JRWK=
LS-411N	M3TZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLFV2ZKSzVyPUCuN\|c3ODZizszN	NXjjW\|BVW0GQR1XS
TK10	NFHmc\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrxTWM2OD1yLkO3PVQ5KM7:TR?=	Ml;tV2FPT0WU
SW1990	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkO1TWM2OD1yLkO4N\|U{KM7:TR?=	MkTmV2FPT0WU
GAMG	NIf4WpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwM{i1Olch\|ryP	MY\TRW5ITVJ?
G-361	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlrtTWM2OD1yLkO4O\|EzKM7:TR?=	M16yTHNCVkeHUh?=
Ca-Ski	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX33Z3FtUUN3ME2wMlM5Pzl{IN88US=>	MkfzV2FPT0WU
786-0	NIDY[2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwM{i4NlMh\|ryP	M3LGZXNCVkeHUh?=
MHH-NB-11	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33ESGlEPTB;MD6zPFk4KM7:TR?=	NYHBS25JW0GQR1XS
OE33	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;yRpR[UUN3ME2wMlM6OTF6IN88US=>	NWrBZ4x6W0GQR1XS
SW954	MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULXVVI5UUN3ME2wMlQxOTNzIN88US=>	MYnTRW5ITVJ?
KYSE-180	NF62TnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwNECxOVEh\|ryP	NUW5SJVoW0GQR1XS
NCI-H720	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrhSWM6UUN3ME2wMlQxOTlzIN88US=>	M2D6XXNCVkeHUh?=
COR-L23	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwNECyPFYh\|ryP	M2n4R3NCVkeHUh?=
PFSK-1	NFrtWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4TtdWlEPTB;MD60NVA6OiEQvF2=	NI\iRVVUSU6JRWK=
FADU	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXBRWpKSzVyPUCuOFEyPzJizszN	NX\OXo04W0GQR1XS
GP5d	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX;0NXpJUUN3ME2wMlQyOjJ3IN88US=>	M1j1[nNCVkeHUh?=
PC-14	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\4TWM2OD1yLkSxOlYyKM7:TR?=	NGPwWY5USU6JRWK=
SJSA-1	M{jGb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwNEG3NVQh\|ryP	NYC5PIF1W0GQR1XS
D-336MG	Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nPTGlEPTB;MD60NlE{QCEQvF2=	M1q2S3NCVkeHUh?=
LOXIMVI	NH\l[pRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfSTWM2OD1yLkSyPFg2KM7:TR?=	MYPTRW5ITVJ?
EFO-27	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWP6RpUyUUN3ME2wMlQ{ODR7IN88US=>	MYnTRW5ITVJ?
A2780	MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVKzZ3hjUUN3ME2wMlQ{OTZ{IN88US=>	NF7JZWVUSU6JRWK=
CAL-12T	M4fydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nhSGlEPTB;MD60N\|I5QCEQvF2=	NYD4OllzW0GQR1XS
ES6	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTBwNESxPFUh\|ryP	NHfMPJdUSU6JRWK=
HCE-T	M3myUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGPwZVFKSzVyPUCuOFQyQDdizszN	NHzuUFdUSU6JRWK=
SK-MES-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjTTWM2OD1yLkS0Nlk{KM7:TR?=	Mn6yV2FPT0WU
Daoy	NFLCO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWiyPVZIUUN3ME2wMlQ2OTB\|IN88US=>	NEixXpFUSU6JRWK=
A2058	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGjoSZdKSzVyPUCuOFUyOzZizszN	MV;TRW5ITVJ?
Hs-578-T	MmXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\WRWlEPTB;MD60OVI4QCEQvF2=	NUjjOWpYW0GQR1XS
TE-11	M1W2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fFSWlEPTB;MD60OVI6OyEQvF2=	MmnpV2FPT0WU
GI-ME-N	NWLWe4FWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPCNnRKSzVyPUCuOFU1PiEQvF2=	MVLTRW5ITVJ?
D-392MG	NVPTU\|lrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjKTWM2OD1yLkS1OlEzKM7:TR?=	NYPDOJd2W0GQR1XS
MOLT-13	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTBwNE[yPVQh\|ryP	NX7LRlRIW0GQR1XS
SK-NEP-1	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIjhVYNKSzVyPUCuOFY1OTlizszN	M1qycHNCVkeHUh?=
KS-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnDW3JPUUN3ME2wMlQ3PjB\|IN88US=>	MVjTRW5ITVJ?
HuP-T4	NWD6XGhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwNE[4Olgh\|ryP	MkTqV2FPT0WU
NCI-H1563	NWXOZmJTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LBT2lEPTB;MD60O\|A{PSEQvF2=	NGLNdGpUSU6JRWK=
U031	M{e3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2jPSmlEPTB;MD60PFI{PCEQvF2=	Mnf0V2FPT0WU
HSC-3	Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLDTWM2OD1yLkS4OlI3KM7:TR?=	MWDTRW5ITVJ?
HT-3	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXvJR\|UxRTBwNEmwN{DPxE1?	NUGxNmdEW0GQR1XS
HGC-27	MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTBwNEmxNVUh\|ryP	NEPrOIhUSU6JRWK=
HT-1080	Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwNEmyO{DPxE1?	NEnGeIxUSU6JRWK=
RT-112	MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTBwNEm5NlEh\|ryP	MYTTRW5ITVJ?
A375	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjJTWM2OD1yLkS5PVIzKM7:TR?=	MUfTRW5ITVJ?
SW626	NUn0PVh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;DfXZFUUN3ME2wMlUxPjN\|IN88US=>	NGT0U4RUSU6JRWK=
SBC-5	NX65UXE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnDS3JjUUN3ME2wMlUyOzR2IN88US=>	MWHTRW5ITVJ?
CAL-51	NFrpdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkT4TWM2OD1yLkWxOFM4KM7:TR?=	MUnTRW5ITVJ?
RKO	NF;icHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTHb3RKSzVyPUCuOVIxOTlizszN	MYnTRW5ITVJ?
HC-1	MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXxNnVSUUN3ME2wMlUzOTF2IN88US=>	MYTTRW5ITVJ?
CHL-1	NYDz[ZNMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHzTWM2OD1yLkWyOVUyKM7:TR?=	M1i5V3NCVkeHUh?=
SK-N-DZ	M{LqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH7GTJJKSzVyPUCuOVMxPzhizszN	M1vzeHNCVkeHUh?=
SNU-423	NEK2[4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVH6[oczUUN3ME2wMlU{PDZ4IN88US=>	NY\yTVR2W0GQR1XS
NB13	M4DJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEOyenlKSzVyPUCuOVM3PTdizszN	NHfjfnpUSU6JRWK=
EW-16	MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;je3JKSzVyPUCuOVM4PzRizszN	MoDnV2FPT0WU
A704	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwNUO4PFEh\|ryP	MYPTRW5ITVJ?
Ca9-22	NVPvd41sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPhemVEUUN3ME2wMlU1ODd5IN88US=>	M3vIW3NCVkeHUh?=
NCI-H1299	M{XrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTaWHlJUUN3ME2wMlU2PThizszN	MkTZV2FPT0WU
LB771-HNC	NELlc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIH3SFBKSzVyPUCuOVU6OzNizszN	M1uwT3NCVkeHUh?=
EW-11	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnX[4tKSzVyPUCuOVY{OjZizszN	NYXkU\|lPW0GQR1XS
LC-2-ad	NX3TSFc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPnU2h{UUN3ME2wMlU3PTJ{IN88US=>	MULTRW5ITVJ?
KNS-62	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjZTWM2OD1yLkW2OVU{KM7:TR?=	MWDTRW5ITVJ?
CAL-62	NIDpO45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvZTWM2OD1yLkW3NVIyKM7:TR?=	NVzQNFZ3W0GQR1XS
SF126	NI\lUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXf5RWpVUUN3ME2wMlU4PDJzIN88US=>	NFy4V4dUSU6JRWK=
OMC-1	MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTBwNUe0PVch\|ryP	NWnrbJJOW0GQR1XS
AGS	NHq4bFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwNUixOlIh\|ryP	MUfTRW5ITVJ?
EW-22	NELr[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoraTWM2OD1yLkW4N\|c2KM7:TR?=	M2[wOnNCVkeHUh?=
KP-N-YS	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jteWlEPTB;MD61PFM5OiEQvF2=	NVryOYJ5W0GQR1XS
BFTC-909	M1LPUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTEVmFKSzVyPUCuOVg5OzNizszN	M2TsNXNCVkeHUh?=
PSN1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPmSZhFUUN3ME2wMlU6OTF6IN88US=>	MmHIV2FPT0WU
NB10	NIfv[VhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTrTWM2OD1yLkW5NVI6KM7:TR?=	NYH6dZR5W0GQR1XS
COLO-800	NFfmdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTPTWM2OD1yLk[wN\|I5KM7:TR?=	Mn;VV2FPT0WU
647-V	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzLNlF3UUN3ME2wMlYyPzh5IN88US=>	NXTQflR7W0GQR1XS
VM-CUB-1	MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwNkG4OlEh\|ryP	NXm1SVVYW0GQR1XS
OS-RC-2	NULFVI1nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVy3fYR6UUN3ME2wMlYzODFizszN	NIPvNWZUSU6JRWK=
IST-SL1	NXG2V3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDoe3V5UUN3ME2wMlYzPzh6IN88US=>	MVHTRW5ITVJ?
NCI-H661	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHzO5ZkUUN3ME2wMlY{PzF{IN88US=>	MXXTRW5ITVJ?
ETK-1	M2\KWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVW3fXI6UUN3ME2wMlY{PzJzIN88US=>	MkjWV2FPT0WU
SW1710	MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmewTWM2OD1yLk[0NFI{KM7:TR?=	NEjXcG5USU6JRWK=
GCT	M4S2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGm0OY9KSzVyPUCuOlQ6OzVizszN	MnjNV2FPT0WU
SKG-IIIa	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojmTWM2OD1yLk[1NFM3KM7:TR?=	NYHlO2dLW0GQR1XS
LU-134-A	M{jTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjncphKSzVyPUCuOlU3PSEQvF2=	M1fhUHNCVkeHUh?=
Becker	NVLRfFZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLqUXZUUUN3ME2wMlY2QDB3IN88US=>	NWDaTYVSW0GQR1XS
PANC-08-13	Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HoWmlEPTB;MD62OlA3QCEQvF2=	NFvmV\|BUSU6JRWK=
SW620	MlXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVfJR\|UxRTBwNk[yNlMh\|ryP	MW\TRW5ITVJ?
AsPC-1	NXXzUpVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLzOFdkUUN3ME2wMlY3OzZzIN88US=>	M1flVnNCVkeHUh?=
LXF-289	M4\XNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfrb29kUUN3ME2wMlY4PjJ3IN88US=>	NHrBRXhUSU6JRWK=
RERF-LC-MS	MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlmyTWM2OD1yLk[3OlcyKM7:TR?=	M4PmV3NCVkeHUh?=
NCI-H1355	NUXU[Yk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXrTWM2OD1yLk[3PFUzKM7:TR?=	MVjTRW5ITVJ?
23132-87	MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwNkizNFYh\|ryP	NHX6PI9USU6JRWK=
BHY	M4DYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHabXhEUUN3ME2wMlY5QDB2IN88US=>	M1e5[XNCVkeHUh?=
C2BBe1	NVexd4VTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwNki5Nlgh\|ryP	M4fJeHNCVkeHUh?=
A172	MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlntTWM2OD1yLk[5NlE4KM7:TR?=	MmntV2FPT0WU
NCI-H727	M3H5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwNkm4NVIh\|ryP	MmTwV2FPT0WU
NB69	M3fWTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDmO3JrUUN3ME2wMlcxPTR7IN88US=>	Mn3jV2FPT0WU
HCC1937	M1[5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnwSodKSzVyPUCuO\|A3OzFizszN	NFvKfGxUSU6JRWK=
HuCCT1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmK4TWM2OD1yLkewO\|Y2KM7:TR?=	MWjTRW5ITVJ?
HH	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwN{C3PFEh\|ryP	MlPOV2FPT0WU
MN-60	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTBwN{KxNlQh\|ryP	NIW1OIhUSU6JRWK=
CFPAC-1	MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1TDdmlEPTB;MD63NlI2PyEQvF2=	NWHQZmFGW0GQR1XS
HOP-62	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLhTWM2OD1yLkeyOlIh\|ryP	NVPCU4VCW0GQR1XS
EW-3	NXz1PXlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH6zNWVKSzVyPUCuO\|M2PTJizszN	MkexV2FPT0WU
SW1417	NXj0NHNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTBwN{O1PVMh\|ryP	Mkf1V2FPT0WU
NCI-H1155	NVi5OHV3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHUSZRKSzVyPUCuO\|M5PjRizszN	NVnLR4tSW0GQR1XS
CAL-54	M1PPSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlixTWM2OD1yLke0NFMh\|ryP	NWLp[JZLW0GQR1XS
Saos-2	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDJTWM2OD1yLke0OVg1KM7:TR?=	NWXVbXVvW0GQR1XS
NCI-H446	M{\3S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPDN21KSzVyPUCuO\|Q5ODZizszN	NX;iPYRJW0GQR1XS
LS-513	MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjmTmpKSzVyPUCuO\|Q6ODhizszN	NG\jcG1USU6JRWK=
PA-1	M{\YT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfXNIoyUUN3ME2wMlc1QTZ6IN88US=>	NF7X[2RUSU6JRWK=
HCC38	NVHhOVFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwN{S5PFQh\|ryP	M3f6S3NCVkeHUh?=
DMS-273	MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fRZ2lEPTB;MD63OVQ2PiEQvF2=	NIrGUWVUSU6JRWK=
U-266	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrjd2piUUN3ME2wMlc3OjZ{IN88US=>	MXXTRW5ITVJ?
HL-60	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWLJR\|UxRTBwN{ezOVUh\|ryP	MkfvV2FPT0WU
UACC-62	MojkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILnXGdKSzVyPUCuO\|c2PTNizszN	MkCzV2FPT0WU
DoTc2-4510	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\STWlEPTB;MD63PFIyOSEQvF2=	NFP3[HpUSU6JRWK=
SW982	NUKzfZBtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwN{i0N\|Ih\|ryP	NWDwemc2W0GQR1XS
8305C	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTlTotCUUN3ME2wMlc5QTN7IN88US=>	MWrTRW5ITVJ?
SW48	NGjxS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;VWYlKSzVyPUCuO\|kzPCEQvF2=	MmjjV2FPT0WU
NB5	M{XGTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XnWWlEPTB;MD63PVY2OSEQvF2=	NELKR2xUSU6JRWK=
J82	NVT4O3ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rVU2lEPTB;MD64NFQ5PyEQvF2=	MXXTRW5ITVJ?
HDLM-2	NEXscFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3wTJlKSzVyPUCuPFE{PDlizszN	M4rUNXNCVkeHUh?=
HEC-1	NEfkSVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;sbZd7UUN3ME2wMlgyOzdzIN88US=>	M3Sxe3NCVkeHUh?=
AU565	NIi2TmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTBwOEK0OEDPxE1?	M4TlZnNCVkeHUh?=
KYSE-520	M2DjTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPOUIxmUUN3ME2wMlgzPjN4IN88US=>	NVvpUmJ3W0GQR1XS
HTC-C3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\DNndKSzVyPUCuPFM1PzRizszN	M3mwWXNCVkeHUh?=
AN3-CA	NFLZTJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPMXYFnUUN3ME2wMlg{PzFzIN88US=>	NXXvR2syW0GQR1XS
KG-1	NUj3XVAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwOES0PFQh\|ryP	NETHcYtUSU6JRWK=
NCI-N87	NXH0NHFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfkV2dKSzVyPUCuPFQ2PTZizszN	NIi5[WNUSU6JRWK=
HN	NFO5VVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwOES1PVEh\|ryP	MlLnV2FPT0WU
SiHa	NYf2c5RqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4n6SmlEPTB;MD64OVg5OiEQvF2=	NXz2SVRuW0GQR1XS
C-33-A	NGrXdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTwXYU{UUN3ME2wMlg3OTh3IN88US=>	MXvTRW5ITVJ?
A673	M{fidmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFHme3JKSzVyPUCuPFY2OzZizszN	NGHlWGhUSU6JRWK=
HSC-2	Mmn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PZOGlEPTB;MD64O\|M{PCEQvF2=	NX7PTYRTW0GQR1XS
LN-405	M{Phd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHPWYYyUUN3ME2wMlg4PzNzIN88US=>	Ml7CV2FPT0WU
HOS	NX[0e4xxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HiU2lEPTB;MD64O\|k6PSEQvF2=	MnyxV2FPT0WU
SF268	NF7GdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PRe2lEPTB;MD64PFA6PyEQvF2=	MmjOV2FPT0WU
DJM-1	MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwOEi2NFIh\|ryP	MX;TRW5ITVJ?
HT-29	NIrNcXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjNbXRKSzVyPUCuPFk1OTdizszN	NWHj[JJ7W0GQR1XS
NCI-H292	NXfWOJVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\RS2lxUUN3ME2wMlg6Pzd5IN88US=>	M1LVbHNCVkeHUh?=
UM-UC-3	NUK5fFhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnMfIVWUUN3ME2wMlkxOzF4IN88US=>	NVfHNGJnW0GQR1XS
VMRC-RCZ	Ml;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfkTWM2OD1yLkmwOVc5KM7:TR?=	NYLxOXdwW0GQR1XS
D-263MG	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwOUC5OFMh\|ryP	NXXFfld5W0GQR1XS
TE-10	M1Licmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jiSmlEPTB;MD65NFk5PCEQvF2=	M4DTdHNCVkeHUh?=
SW1088	M3P1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Xhd2lEPTB;MD65NVU2OiEQvF2=	M{LKfHNCVkeHUh?=
NCI-H1048	NFWxTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmq1TWM2OD1yLkmxPFUzKM7:TR?=	M4LrbHNCVkeHUh?=
A431	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTBwOUK0OVIh\|ryP	NUexVFU4W0GQR1XS
SW1783	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYqzUGhlUUN3ME2wMlk{OjVzIN88US=>	M3\MVnNCVkeHUh?=
NCI-H2452	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDISXFUUUN3ME2wMlk{PTV5IN88US=>	M3LIfnNCVkeHUh?=
OAW-42	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUf3dIc6UUN3ME2wMlk{PjZ3IN88US=>	MUTTRW5ITVJ?
HuO-3N1	NF3KbHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTab\|RUUUN3ME2wMlk1ODl{IN88US=>	M1HtSXNCVkeHUh?=
K5	NILjb25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\pTmlEPTB;MD65OFEzPyEQvF2=	MoXQV2FPT0WU
SW1573	M2\1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTBwOUSyNlch\|ryP	MXvTRW5ITVJ?
NCI-H1792	NUXMTnRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofnTWM2OD1yLkm0NlM4KM7:TR?=	MonTV2FPT0WU
HCC1187	NELtTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFj4RnhKSzVyPUCuPVY4PDlizszN	MUDTRW5ITVJ?
HCE-4	M1XtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGWwbJJKSzVyPUCuPVY6PiEQvF2=	NHqyeYFUSU6JRWK=
HPAF-II	NUTCRmo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVXvZ\|BDUUN3ME2wMlk4ODJ6IN88US=>	NH23O3FUSU6JRWK=
MEL-HO	M{nwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MW\JR\|UxRTBwOUe5OFUh\|ryP	NU\CdZgyW0GQR1XS
LCLC-103H	Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfyTWM2OD1yLkm4NFI4KM7:TR?=	MofyV2FPT0WU
CAL-33	M3P5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInNWYJKSzVyPUCuPVg{PzhizszN	NXjBfZlvW0GQR1XS
NB6	MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXrOWNKSzVyPUCuPVg1PjJizszN	M1:4UnNCVkeHUh?=
BFTC-905	M3:zXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mme2TWM2OD1yLkm4OFc{KM7:TR?=	MUPTRW5ITVJ?
NMC-G1	Mo\US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnCXIJtUUN3ME2wMlk5PTl{IN88US=>	Mk\CV2FPT0WU
RCM-1	Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPEb3l7UUN3ME2wMlk6OjV6IN88US=>	NIfENodUSU6JRWK=
COLO-320-HSR	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInLRndKSzVyPUGuNFA1OTJizszN	M1zEN3NCVkeHUh?=
NCI-H2030	MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\acZFyUUN3ME2xMlAyQDF\|IN88US=>	M{GxT3NCVkeHUh?=
SCC-4	NWjoU5FoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfnR4hKSzVyPUGuNFE5PTlizszN	NV;FSHQ6W0GQR1XS
KYSE-410	M4nMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTFwMEO1NkDPxE1?	NFKw[npUSU6JRWK=
NCI-H1650	NVX0fFVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXtOoQ3UUN3ME2xMlA{QTdzIN88US=>	MUfTRW5ITVJ?
S-117	M{DnNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTFwMESg{txO	M{TOe3NCVkeHUh?=
GAK	M4nqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTFwMEWwO\|Uh\|ryP	MU\TRW5ITVJ?
KYSE-450	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGThPWpKSzVyPUGuNFU{OzZizszN	M1LrTXNCVkeHUh?=
M059J	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTFwME[4Nlgh\|ryP	MlTrV2FPT0WU
LAN-6	Ml63S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGi1V5JKSzVyPUGuNFc4PzNizszN	M4XrcHNCVkeHUh?=
NCI-H1651	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIW4clFKSzVyPUGuNFk{PTJizszN	NV3qOGt[W0GQR1XS
KMOE-2	M1vVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonRTWM2OD1zLkGwPVc{KM7:TR?=	MXHTRW5ITVJ?
SN12C	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTFwMUG3PFUh\|ryP	M3f3SXNCVkeHUh?=
SW900	M4r4Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXaTWM2OD1zLkGyNlUyKM7:TR?=	NV\NOpIyW0GQR1XS
TE-8	NYT1RXB2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLqN\|VzUUN3ME2xMlEzOjlzIN88US=>	NHmxWGVUSU6JRWK=
HO-1-N-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTFwMUSzOVMh\|ryP	MXXTRW5ITVJ?
BHT-101	NULnTHZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVmyRpFKUUN3ME2xMlE1PzF2IN88US=>	NGXNTFhUSU6JRWK=
639-V	MnftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fSWWlEPTB;MT6xOlY4KM7:TR?=	NUfUW4E3W0GQR1XS
RVH-421	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTFwMUmzOFch\|ryP	M1vEc3NCVkeHUh?=
SW780	NGPLRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfTU4dKSzVyPUGuNVk2OTVizszN	NXLrXGJlW0GQR1XS
SNB75	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIi5b3FKSzVyPUGuNVk5OTlizszN	NEPobJdUSU6JRWK=
U-87-MG	M4XpV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGraNYJKSzVyPUGuNlE{OzRizszN	NHTYR\|dUSU6JRWK=
TE-1	NXixR5pkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDydGJKSzVyPUGuNlE{PjdizszN	MnuxV2FPT0WU
CAS-1	NWqxW5pwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;uTI5UUUN3ME2xMlIyPDF6IN88US=>	M3vm[nNCVkeHUh?=
MKN7	NGrRPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWntSnlIUUN3ME2xMlIyPDd6IN88US=>	NIPCOWxUSU6JRWK=
KM-H2	NXLyepptT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTFwMkG3O\|Mh\|ryP	M1SwPXNCVkeHUh?=
NCI-H1693	NEnYbGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjBbphkUUN3ME2xMlIzPzV6IN88US=>	MmL6V2FPT0WU
KGN	NWLDTGtCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXWyb2wzUUN3ME2xMlI{OzV7IN88US=>	MUjTRW5ITVJ?
NCI-H2347	M3XaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXie49KSzVyPUGuNlM2OjVizszN	MXfTRW5ITVJ?
MFM-223	M{Dx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTFwMkSzOFMh\|ryP	MoPzV2FPT0WU
OCI-AML2	NEW0bGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLrTWM2OD1zLkK2OlY3KM7:TR?=	MYrTRW5ITVJ?
SAS	NE\MW3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTFwMk[2O\|Ih\|ryP	M1PhcnNCVkeHUh?=
BT-549	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXIcHNJUUN3ME2xMlI3Pzh{IN88US=>	M4nOVHNCVkeHUh?=
NCI-H2228	M1vvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH[2[I5KSzVyPUGuNlg3PCEQvF2=	NHW3NXJUSU6JRWK=
BxPC-3	NX[ye5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXj6[4FIUUN3ME2xMlMxPjd{IN88US=>	NXvsfnJTW0GQR1XS
SCH	NGXGTlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLMSFNKSzVyPUGuN\|I2ODNizszN	M{P4NXNCVkeHUh?=
GMS-10	NFXjW49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rpV2lEPTB;MT6zOFU2OSEQvF2=	M4PISHNCVkeHUh?=
GB-1	NH3FSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\hTWM2OD1zLkO3OVY1KM7:TR?=	NF7SOYFUSU6JRWK=
NCI-H520	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPaVJg1UUN3ME2xMlM5OTZ6IN88US=>	NWfaNFYxW0GQR1XS
GCIY	M3:0Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DnWGlEPTB;MT6zPVA2OSEQvF2=	MkfzV2FPT0WU
HuH-7	NYqz[oVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2C0e2lEPTB;MT6zPVUxOSEQvF2=	NGnWeWlUSU6JRWK=
IA-LM	NYi2ZoVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjtOohDUUN3ME2xMlM6QTh4IN88US=>	M2nMd3NCVkeHUh?=
BB49-HNC	M{jLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1f2XGlEPTB;MT60NFI{OSEQvF2=	M{[xWHNCVkeHUh?=
Calu-6	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXe3Rnh{UUN3ME2xMlQyOTh5IN88US=>	NUjBT\|N4W0GQR1XS
NCI-H650	NIq2SlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEi3O2pKSzVyPUGuOFE4QTVizszN	MkDoV2FPT0WU
TE-5	MoH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\rTppKSzVyPUGuOFE6PTRizszN	MoG5V2FPT0WU
KINGS-1	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXvwXI5yUUN3ME2xMlQzODF6IN88US=>	NX;2OJdpW0GQR1XS
HCT-116	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4m3Z2lEPTB;MT60NlE4PiEQvF2=	M1L3cXNCVkeHUh?=
NCI-H1573	NYrte\|NOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWS1S4VkUUN3ME2xMlQzOjV5IN88US=>	MmfXV2FPT0WU
NCI-H358	NHHLVYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTFwNEOxNlgh\|ryP	MkDiV2FPT0WU
LNCaP-Clone-FGC	Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTFwNESzNVkh\|ryP	M2rCWXNCVkeHUh?=
KP-4	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWTxeWJqUUN3ME2xMlQ3OTVzIN88US=>	NICzUJhUSU6JRWK=
LK-2	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTjTWM2OD1zLkS2N\|gzKM7:TR?=	NX7KOYFFW0GQR1XS
EFM-19	M3HpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{m4O2lEPTB;MT60PFExPCEQvF2=	MkfZV2FPT0WU
GT3TKB	NVnTdZAxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTFwNEi2NVMh\|ryP	MV\TRW5ITVJ?
A549	M{XqdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33GNWlEPTB;MT60PFg{OyEQvF2=	MofqV2FPT0WU
no-11	M1\Kemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHO5T21KSzVyPUGuOFkxOjZizszN	MmDqV2FPT0WU
SK-N-FI	NGHxPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M364cWlEPTB;MT60PVM5KM7:TR?=	NYLxZWt{W0GQR1XS
NCI-H2170	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\WO4ZYUUN3ME2xMlUzOzF\|IN88US=>	NFXzSJhUSU6JRWK=
NCI-H460	NWnNR\|FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnftTWM2OD1zLkWyPVYyKM7:TR?=	MUDTRW5ITVJ?
NCI-H526	NHG3XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnMe\|dKSzVyPUGuOVM4ODZizszN	MWDTRW5ITVJ?
KYSE-510	MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTFwNUiyOUDPxE1?	MnThV2FPT0WU
YKG-1	NHTWcZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{PWRWlEPTB;MT61PFMzQCEQvF2=	NXnGW3R1W0GQR1XS
EW-18	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPET\|hLUUN3ME2xMlYxOjJ5IN88US=>	MWXTRW5ITVJ?
MDA-MB-231	M1L4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTFwNkCzPEDPxE1?	NIS2VJdUSU6JRWK=
HT55	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fob2lEPTB;MT62NFU6OSEQvF2=	MWfTRW5ITVJ?
NCI-H1793	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\DTWM2OD1zLk[xN\|Q2KM7:TR?=	M1ex[nNCVkeHUh?=
TE-9	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXtN\|FWUUN3ME2xMlY{PDV4IN88US=>	NUHQOYZkW0GQR1XS
DSH1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfLOGJKSzVyPUGuOlkzPTZizszN	NFjselRUSU6JRWK=
A101D	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXUd\|JKSzVyPUGuOlk6QDNizszN	NEnzdJNUSU6JRWK=
DB	M1vCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX7JR\|UxRTFwN{CwOlch\|ryP	NX\RRlhmW0GQR1XS
ME-180	M33NfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1v5[GlEPTB;MT63NVc5PSEQvF2=	M1n0UHNCVkeHUh?=
BT-20	NV;uO2poT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTFwN{K0NFch\|ryP	MYnTRW5ITVJ?
A498	NXz1codtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTFwN{K5OlMh\|ryP	NVXEfYlyW0GQR1XS
UMC-11	NXT3TGl7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTFwN{[3OFkh\|ryP	NWfuU5VDW0GQR1XS
EC-GI-10	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTFwN{e1OVYh\|ryP	M3rqeHNCVkeHUh?=
NCI-H630	Mn32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfCVodxUUN3ME2xMlc5PjR{IN88US=>	Mm\HV2FPT0WU
EGI-1	Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTFwOECyOlch\|ryP	NYHNO2pxW0GQR1XS
22RV1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWHwO2ljUUN3ME2xMlgxQDV\|IN88US=>	Ml3oV2FPT0WU
LS-123	NFTpXY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoT2TWM2OD1zLkixNlE1KM7:TR?=	NWDINHdCW0GQR1XS
OAW-28	Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XFbmlEPTB;MT64OFc1PiEQvF2=	MVnTRW5ITVJ?
CaR-1	NISyd3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTFwOEewO{DPxE1?	MljmV2FPT0WU
HT	NFfzXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIW5TJpKSzVyPUGuPFc{PDJizszN	M1XyUnNCVkeHUh?=
BCPAP	NFjKXHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTFwOEi2O\|Yh\|ryP	NFTaZZJUSU6JRWK=
RMG-I	M32xNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XO[GlEPTB;MT65NFc5PyEQvF2=	NH72eHhUSU6JRWK=
C8166	MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTFwOUC5N\|Ih\|ryP	M17TfXNCVkeHUh?=
TGBC1TKB	NFz3OFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;6SWlEPTB;MT65NlA{PSEQvF2=	MXXTRW5ITVJ?
SCC-9	NULPbZdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPS[ot2UUN3ME2xMlk6OTB3IN88US=>	MWXTRW5ITVJ?
EKVX	NVTxUY9ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHrTWM2OD1{LkCwNVU1KM7:TR?=	MoDVV2FPT0WU
KU-19-19	NYjBU2g2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoW4TWM2OD1{LkCwN\|czKM7:TR?=	NGPPPGVUSU6JRWK=
K-562	M3TZTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnnBTWM2OD1{LkCwPFk5KM7:TR?=	MkPxV2FPT0WU
SW962	NFjDRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkS2TWM2OD1{LkC0NFU6KM7:TR?=	NXzmV2s{W0GQR1XS
MDA-MB-453	NXH6RpVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\1OGlEPTB;Mj6wOVQ1OiEQvF2=	MVnTRW5ITVJ?
BPH-1	MkHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn7TTWM2OD1{LkC3NFk5KM7:TR?=	MlfVV2FPT0WU
DK-MG	NHLLXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnofmxOUUN3ME2yMlA5PjB\|IN88US=>	NWnpSYlGW0GQR1XS
Capan-2	NYPYbXN1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnsUZFKSzVyPUKuNVAxPDFizszN	MVTTRW5ITVJ?
SCC-15	NUWxRW52T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVTJR\|UxRTJwMUK1OFEh\|ryP	M2L3SnNCVkeHUh?=
DOK	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkWxTWM2OD1{LkGzNVQ4KM7:TR?=	MkC1V2FPT0WU
YAPC	NHrMe5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTJwMUWzNFch\|ryP	M1nrPHNCVkeHUh?=
AM-38	M2TSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPrV41KSzVyPUKuNVcxOTVizszN	M3rHd3NCVkeHUh?=
EFO-21	M3zLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPjWVFKSzVyPUKuNVc4QDhizszN	MkK3V2FPT0WU
A388	NVHSWlBFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWrJR\|UxRTJwMUmyO\|Eh\|ryP	NXHWcnp{W0GQR1XS
RH-18	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfWTWM2OD1{LkG5N\|Y6KM7:TR?=	MVjTRW5ITVJ?
NCI-H1581	MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTJwMUm1PVYh\|ryP	MnjHV2FPT0WU
COLO-668	Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTJwMkm5O\|Mh\|ryP	NFvmPXZUSU6JRWK=
RPMI-2650	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLsO2xIUUN3ME2yMlMzPjV7IN88US=>	NXO1XHJbW0GQR1XS
HMV-II	NH70OJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTJwM{O4Olgh\|ryP	NXLqcnY{W0GQR1XS
NCI-H2342	MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3GxO2lEPTB;Mj6zOFYxOyEQvF2=	MmjPV2FPT0WU
SH-4	NV7TZppZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fkfmlEPTB;Mj6zPFIxPCEQvF2=	M1LxdHNCVkeHUh?=
L-428	NEPoNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn24TWM2OD1{LkO4O\|k1KM7:TR?=	MXzTRW5ITVJ?
U-118-MG	NVfnelVlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrHTWM2OD1{LkO5PFA2KM7:TR?=	NFvw[o1USU6JRWK=
RO82-W-1	M3m0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLYcHZIUUN3ME2yMlQ{PzJ5IN88US=>	MVzTRW5ITVJ?
NCI-H2291	NH\WUZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTJwNE[5PVQh\|ryP	MX\TRW5ITVJ?
SK-OV-3	M3\CT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vVOGlEPTB;Mj61NFI1QSEQvF2=	Mor3V2FPT0WU
NCI-H441	NYnYV4RbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYDncmFmUUN3ME2yMlUxOzB3IN88US=>	NEj5c3RUSU6JRWK=
NCI-H2009	NVL4VmdWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTJwNUK5N\|Qh\|ryP	MofDV2FPT0WU
LB2518-MEL	NXzHTWV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETYenlKSzVyPUKuOVM4PDdizszN	M{DIdnNCVkeHUh?=
PANC-10-05	NVTwfYIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37XPWlEPTB;Mj62NVEyPiEQvF2=	MYTTRW5ITVJ?
CAL-85-1	Mmi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LY[mlEPTB;Mj62OlE3OSEQvF2=	NF3OR5NUSU6JRWK=
PC-3	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jTSWlEPTB;Mj62OlYyOSEQvF2=	MYTTRW5ITVJ?
COLO-824	M{e3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7LZVhPUUN3ME2yMlY4Ozd2IN88US=>	M1zRdHNCVkeHUh?=
D-502MG	M373UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4G4WGlEPTB;Mj63NFQxPiEQvF2=	M{TScnNCVkeHUh?=
SBC-1	NWLze\|l5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mme4TWM2OD1{LkexOlI4KM7:TR?=	M{H4dnNCVkeHUh?=
CAPAN-1	NEXRfHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17TbWlEPTB;Mj63NVk1QSEQvF2=	NVP3RocxW0GQR1XS
D-247MG	NGXDcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmXHTWM2OD1{LkezO\|U3KM7:TR?=	NXrVZo5sW0GQR1XS
CAL-39	NYDHSWdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlr3TWM2OD1{Lki2N\|g6KM7:TR?=	MUXTRW5ITVJ?
NCI-H2087	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoLFTWM2OD1{Lki4OFMyKM7:TR?=	MULTRW5ITVJ?
NB7	NX7SXVdtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTJwOUKxN\|kh\|ryP	NInZU2lUSU6JRWK=
NCI-H1437	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDSTWM2OD1{LkmyNlU4KM7:TR?=	NIX5O\|NUSU6JRWK=
RD	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M12zTWlEPTB;Mj65PVk{QSEQvF2=	MkTHV2FPT0WU
TCCSUP	NXLjRYdGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlrYTWM2OD1\|LkCyOlM3KM7:TR?=	NGLSTXVUSU6JRWK=
MKN28	NY\LeGt5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Xj[mlEPTB;Mz6wN\|Q3OyEQvF2=	NFn1NnpUSU6JRWK=
NCI-H596	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zhWWlEPTB;Mz6wOlcyKM7:TR?=	NFvF[GRUSU6JRWK=
SW948	NV7Fc5J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfEVGhKSzVyPUOuNFk3QTNizszN	MVXTRW5ITVJ?
WM-115	M3Xue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfGcFNKSzVyPUOuNVE5OjdizszN	MYPTRW5ITVJ?
HCC1954	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NG\wcnZKSzVyPUOuNVIyPDFizszN	M4fncHNCVkeHUh?=
MS-1	NED5[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mof0TWM2OD1\|LkG4OFc1KM7:TR?=	MX;TRW5ITVJ?
SW13	NFjwdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnDTWM2OD1\|LkKzNlYh\|ryP	NFTxe2xUSU6JRWK=
OE19	NX7DN3luT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTNwMki0PFkh\|ryP	M4G3OXNCVkeHUh?=
HT-1197	Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTNwMkmxO\|kh\|ryP	Ml3CV2FPT0WU
HLE	Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvHTWM2OD1\|LkOyPFEh\|ryP	MYXTRW5ITVJ?
NUGC-3	NIq3b2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7BTWM2OD1\|LkS0O\|YyKM7:TR?=	NX\0TZdHW0GQR1XS
UACC-257	M1rkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1j1ZWlEPTB;Mz61NlQyPyEQvF2=	MX;TRW5ITVJ?
SK-MEL-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLuOWRKUUN3ME2zMlU{OjF2IN88US=>	M3zWS3NCVkeHUh?=
KNS-81-FD	MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXVTWM2OD1\|LkW2NkDPxE1?	NUfvTVZtW0GQR1XS
MZ1-PC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTNwNUe5PFYh\|ryP	MlyyV2FPT0WU
KLE	M4CwVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIi0TZBKSzVyPUOuOVk5PjdizszN	MlmxV2FPT0WU
NCI-H2052	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDUelVWUUN3ME2zMlYxODB7IN88US=>	NIrQR49USU6JRWK=
NCI-H1838	M1Lwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XsSGlEPTB;Mz64NVEyQSEQvF2=	MXPTRW5ITVJ?
NCI-H1623	NWXEeGNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjhN3pKSzVyPUSuNFE{QTZizszN	MkDEV2FPT0WU
SCC-25	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml;vTWM2OD12LkKzOVk4KM7:TR?=	NVP0U3JEW0GQR1XS
CP66-MEL	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXkN3FqUUN3ME20MlI2OTlzIN88US=>	MX;TRW5ITVJ?
TE-12	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWL0ZWM{UUN3ME20MlI6OjdzIN88US=>	MnTzV2FPT0WU
LU-99A	MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGfCTphKSzVyPUSuN\|E{PDVizszN	MXTTRW5ITVJ?
CAMA-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTRwM{WyJO69VQ>?	MYjTRW5ITVJ?
SK-MEL-30	NIjUeFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PITGlEPTB;ND60NVkyOyEQvF2=	NITFbG5USU6JRWK=
KURAMOCHI	MlnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDLfmhKSzVyPUSuOFU2OjhizszN	M1fDOnNCVkeHUh?=
BEN	NU\QWWIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\ZNmlEPTB;ND61NlM3OiEQvF2=	M37MV3NCVkeHUh?=
NCI-H226	M4XhN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;aWmlEPTB;ND61OFg4OSEQvF2=	MmnoV2FPT0WU
CAL-27	Mn:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2OxbmlEPTB;ND63NVY6PCEQvF2=	MnzYV2FPT0WU
G-401	NIHRelFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvWTWM2OD12LkizPFQyKM7:TR?=	Mn:wV2FPT0WU
CAL-120	M{n1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\kUpdtUUN3ME20Mlg1QTlzIN88US=>	NXP5bppTW0GQR1XS
DMS-114	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTVwMUS1NFYh\|ryP	Mn3GV2FPT0WU
KYSE-70	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\xTWM2OD13LkG0PFU6KM7:TR?=	M{HHRnNCVkeHUh?=
NCI-H1648	NG\m[2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzu[VlKSzVyPUWuNlk4QDJizszN	NXvvOJFoW0GQR1XS
MDA-MB-175-VII	MmPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTVwNESwNVQh\|ryP	NIT3TXlUSU6JRWK=
NCI-H2029	NGHKTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTVwNEiwNlIh\|ryP	M3n4ZnNCVkeHUh?=
LS-1034	NH36[nFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfxTWM2OD13Lk[2PFg6KM7:TR?=	NVq2[mo3W0GQR1XS
LB831-BLC	MmHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4PR[WlEPTB;NT63NFM1PSEQvF2=	MYDTRW5ITVJ?
MDA-MB-415	M3K5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2SwfGlEPTB;NT63NFgyKM7:TR?=	MV7TRW5ITVJ?
TE-6	MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTVwN{SxPFIh\|ryP	M37abHNCVkeHUh?=
SK-MEL-24	MlHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfzU45KSzVyPUWuO\|Q2PjRizszN	MnLPV2FPT0WU
HUTU-80	MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXTUG9UUUN3ME21Mlc2OzN\|IN88US=>	MWjTRW5ITVJ?
OCUB-M	M2LGPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTVwN{e1OlMh\|ryP	M4fUU3NCVkeHUh?=
IGR-1	NF3QXnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTlcIZFUUN3ME21Mlg3QDl2IN88US=>	M1TOUnNCVkeHUh?=
NCI-H747	NUjYSotLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml;WTWM2OD14LkK0OVg2KM7:TR?=	NYmxUWVEW0GQR1XS
COLO-680N	NXq5[FBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTZwM{m0NFMh\|ryP	MVTTRW5ITVJ?
NB12	NVzzNVlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M16xUWlEPTB;Nj63PVczOiEQvF2=	NULt[XVWW0GQR1XS
SNU-449	M1jsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTZwOUm1PVEh\|ryP	MUDTRW5ITVJ?
D-542MG	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIj0SmtKSzVyPUeuNVIzQTlizszN	NWnldnprW0GQR1XS
COLO-792	NWfOUXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX20dnd4UUN3ME23Mlg4OTJ5IN88US=>	NVXD[4pKW0GQR1XS
NCI-H810	NWfZeGNCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:1TWM2OD16LkCyPVg1KM7:TR?=	MWPTRW5ITVJ?
T47D	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfp[VhKSzVyPUiuNVYxOjRizszN	M3PnUHNCVkeHUh?=
Calu-3	NV65SFJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPveIdKSzVyPUiuNlg5QDZizszN	NGP2NYxUSU6JRWK=
COLO-741	MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlLUTWM2OD16LkmzNFk{KM7:TR?=	M2nT[3NCVkeHUh?=
LU-135	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH76e3NKSzVyPUmuNFM1PTJizszN	NY\aXZN7W0GQR1XS
COLO-678	NXHTNnV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHQV4JKSzVyPUmuNlg5PDRizszN	NUn3Vm85W0GQR1XS
NCI-H2126	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFvLWpFKSzVyPUmuN\|M6OTlizszN	NXLROFNCW0GQR1XS
SK-MEL-28	Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2H1VWlEPTB;OT61N\|U6PiEQvF2=	MlXsV2FPT0WU
MFE-280	NFrNVYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTFyLkCyNlkh\|ryP	MkOyV2FPT0WU
DBTRG-05MG	M{nhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjFVmJKSzVyPUGwMlQ{PjlizszN	MYHTRW5ITVJ?
RCC10RGB	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX32NFc3UUN3ME2xNE42OjV3IN88US=>	NYXPRY86W0GQR1XS
NTERA-S-cl-D1	M{XDWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzCRnVKSzVyPUGwMlY5PTJizszN	NWqzTo5OW0GQR1XS
C3A	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Hrb2lEPTB;MUKuN\|E4OiEQvF2=	NVTKfFJWW0GQR1XS
MHH-ES-1	M3W4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3K5ZmlEPTB;MUKuOVI5PCEQvF2=	MY\TRW5ITVJ?
LU-139	NWr5WHpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHKTWM2OD1zMj62N\|M{KM7:TR?=	NVHReYVFW0GQR1XS
KNS-42	M3\pdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTF{Lki3O\|Eh\|ryP	NEXrRW9USU6JRWK=
MCF7	M1j1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUXufYFwUUN3ME2xN{4zOzZ3IN88US=>	MoPzV2FPT0WU
SW872	M4XnRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIm4coNKSzVyPUG0MlU1PjFizszN	MkXTV2FPT0WU
HT-1376	NX\WdFF[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDnXZBKSzVyPUG0Mlg2QDJizszN	M3TObnNCVkeHUh?=
NCI-SNU-5	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DyTGlEPTB;MUWuNVc1OSEQvF2=	MULTRW5ITVJ?
NCI-H2405	NIrIR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTF3LkS0O\|Qh\|ryP	MkP1V2FPT0WU
KYSE-150	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTF3Lke2NVEh\|ryP	MWnTRW5ITVJ?
SW837	NWHBWYsxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjtXGZ7UUN3ME2xOk4xOTJ2IN88US=>	MmHwV2FPT0WU
LU-65	M1y4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;GXXo3UUN3ME2xPU44OjZizszN	MmjnV2FPT0WU
JEG-3	NWexTY1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPTbodKSzVyPUKwMlM2PzdizszN	MWTTRW5ITVJ?
SK-MEL-1	NVHHWpBoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTJyLke4N\|Yh\|ryP	M3jafXNCVkeHUh?=
SK-HEP-1	NELlTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWjJR\|UxRTJzLkW1OFEh\|ryP	M3TFU3NCVkeHUh?=
NCI-H1770	NIfyV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTuTWM2OD1{Mz60NFg3KM7:TR?=	Mn3NV2FPT0WU
MG-63	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4DBOGlEPTB;MkOuO\|Y4OyEQvF2=	NF;vSlhUSU6JRWK=
ECC10	M3fkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUOyd2s2UUN3ME2yOU42PzFizszN	MWfTRW5ITVJ?
SW1463	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPTeI42UUN3ME2yO{45OzF4IN88US=>	MmjNV2FPT0WU
JVM-2	MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1zrXmlEPTB;MkiuN\|I1QCEQvF2=	MnPWV2FPT0WU
HCT-15	NImyfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIPnfVBKSzVyPUK4MlQyQTJizszN	MnTlV2FPT0WU
CAL-72	NWXSbVd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fZZWlEPTB;M{GuOFkyOiEQvF2=	NGfVVGpUSU6JRWK=
HCC2218	MnrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknGTWM2OD1\|Mj64PFU5KM7:TR?=	NHjXO4pUSU6JRWK=
BT-474	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTN\|LkC4OFMh\|ryP	NV\2fJJ3W0GQR1XS
NCI-H1092	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTN\|LkWxOFUh\|ryP	MVXTRW5ITVJ?
Mo-T	M2S3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmjMTWM2OD1\|Nz6zOVg2KM7:TR?=	M1u3RnNCVkeHUh?=
DU-145	M2fKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T2S2lEPTB;NECuOlI6PSEQvF2=	NHrLfZNUSU6JRWK=
NCI-H1666	M4PNUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVfJR\|UxRTR{LkS0PFgh\|ryP	NGDTTWNUSU6JRWK=
IST-MES1	MnHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTR4LkSxPVYh\|ryP	M{jwcHNCVkeHUh?=
SW1116	M3;5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4W4e2lEPTB;NEiuNVc2PiEQvF2=	NWHnSGQxW0GQR1XS
MZ2-MEL	NFy2VIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3[yUWlEPTB;NEiuOVAzPiEQvF2=	NHy2[VZUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pChk1 / Chk1 / Wee1 / p21 / p53 ; PubMed: 29963769 Cancer Med Immunoblotting analysis of CAL39 and SW954 cells showing increase in CHK1 phosphorylation after exposure to AZD7762 for 24 hours. β‐actin is used as loading control. Representative data from n = 3 experiments.	29963769
Growth inhibition assay	Cell viability; PubMed: 23715154 Cancer Discov Lkb1-wt (634, 855, and 857) and Lkb1-null (t2, t4, and t5) cell lines were plated into 96-well plates at 2000 cells/well in 150 ml medium containing the indicated concentrations of AZD7762 or CHIR124 for 3 days. Viable cells were then counted with Dojindo’s Cell Counting Kit-8 assay. The data represent mean ± SD for 3 repeats. GI50 was calculated with GraphPad.	23715154

In vivo

AZD7762 alone at 25 mg/kg shows little antitumor activity in the H460-DNp53 xenograft mice and SW620 xenograft mice, but when administrated in combination with gemcitabine (60 mg/kg), AZD7762 shows significant antitumor efficacy in the two xenografts mice with a log cell kill of 0.9 or percent treated/control (%T/C) of 26 even at low dose of 12.5 mg. Dosing of AZD7762 in combination with gemcitabine (10 mg/kg) in the H460-DNp53 xenograft rat inhibits the tumor volume in a dose-dependent manner with the %T/C values of 48 and 32 for 10 and 20 mg/kg AZD7762, respectively. AZD7762 (25 mg/kg) in combination with irinotecan (25 or 50 mg/kg) causes complete tumor regression in the SW620 xenograft mice with the %T/C increasing significantly to -66% and -67%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Chk1 Kinase Assay: Recombinant human Chk1 is expressed as a glutathione S-transferase fusion in insect cells using a baculovirus vector and purified by glutathione affinity chromatography. A synthetic peptide substrate (N-biotinylaminohexanoyl-KKVSRSGLYRSPMPENLNRPR) for Chk1 is synthesized. Final assay concentrations of peptide and ATP (cold + 40 nCi [³³P]ATP) are 0.8 and 1 μM, respectively. Different concentrations of AZD7762, buffer containing peptide and chk1 kinase and ATP, are added sequentially to a 384-well assay plate. The plate is incubated for 2 hours, reaction is stopped by the addition of buffer containing EDTA and scintillation proximity assay beads, and plates are read using a TopCount reader. Data analysis is carried out to determinate a dose response (IC50).
Cell Research:^[1]	- Collapse Cell lines: HT29, SW620 and MDA-MB-231 cells Concentrations: Dissolved in DMSO, final concentration ~12.5 μM Incubation Time: 20 or 48 hours Method: For the checkpoint abrogation assay, HT29 cells are treated for 2 hours with camptothecin (topoisomerase I inhibitor; 0.07 μg/mL) to induce the G2 checkpoint. Cells are then treated for 20 hours with a 12-point titration of AZD7762 (12.5 μM to 6 nM) plus nocodazole. Cells are fixed with 3.7% formaldehyde for 1 hour, permeabilized with PBS containing 0.05% Triton X, and incubated with anti-phH3 antibody for 1 hour followed by Alexa Fluor 488 anti-rabbit and Hoechst stain for 1 hour. Mitotic index is determined on the ArrayScan and expressed as the percentage of cells undergoing mitosis. For the potentiation assays, SW620 or MDA-MB-231 cells are dosed for 24 hours with a 9-point titration of gemcitabine ranging from 0.01 to 100 nM with a constant dose of AZD7762 (300 nM). After 24 hours, medium is removed and AZD7762 alone is added back to the wells for an additional 24 hours. Cells are then incubated in AZD7762-free medium for an additional 72 hours. The effect on cell proliferation is determined by MTT. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Male NCr mice implanted s.c. with H460-DNp53 cells or SW620, and male rnu rats implanted s.c. with H460-DNp53 cells Formulation: Formulated in 11.3% hydroxyproplyl-β-cyclodextrin Dosages: ~25 mg/kg Administration: Injection i.v. (Only for Reference)

References

[1] Zabludoff SD, et al. Mol Cancer Ther, 2008, 7(9), 2955-2966.

Solubility (25°C)

In vitro	DMSO	50 mg/mL (137.96 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download AZD7762 SDF

Molecular Weight	362.42
Formula	C₁₇H₁₉FN₄O₂S
CAS No.	860352-01-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
If I want to use the inhibitor for i.p. injection, can I use DMSO to dissolve it?
Answer:
Since DMSO has low toxicity with i.p. injection, hydroxyproplyl-β-cyclodextrin is consider a safer co-solvent in compound formulation. In a previous literature report, 11.3% hydroxyproplyl-β-cyclodextrin was used to formulate this compound for i.v. injection.

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Selective CHK Inhibitor

MK-8776 (SCH 900776) : Chk1-selective, IC50=3 nM.
Most Potent CHK Inhibitor

CHIR-124 : Chk1, IC50=0.3 nM.
CHK Inhibitor in Clinical Trial

MK-8776 (SCH 900776) : Phase II for Relapsed Acute Myeloid Leukemia.
Classic CHK Inhibitor

PF-477736 : Selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes.

Related Chk Products

Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
ML141 ^New

ML141 (CID-2950007), is demonstrated to be a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase suitable for in vitro assays, with IC50 of 200 nM and selectivity against other members of the Rho family of GTPases (Rac1, Rab2, Rab7).
Rabusertib (LY2603618)

Rabusertib (LY2603618) is a highly selective Chk1 inhibitor with potential anti-tumor activity in a cell-free assay. IC50=7 nM, showing approximately 100-fold more potent against Chk1 than against any of the other protein kinases evaluated.
CHIR-124

CHIR-124 is a novel and potent Chk1 inhibitor with IC50 of 0.3 nM in a cell-free assay. It shows 2,000-fold selectivity against Chk2, 500- to 5,000-fold less activity against CDK2/4 and Cdc2.
MK-8776 (SCH 900776)

MK-8776 (SCH 900776) is a selective Chk1 inhibitor with IC50 of 3 nM in a cell-free assay. It shows 500-fold selectivity against Chk2. Phase 2.
PF-477736

PF-477736 is a selective, potent and ATP-competitive Chk1 inhibitor with K_i of 0.49 nM in a cell-free assay and also inhibits VEGFR2, Aurora-A, FGFR3, Flt3, Fms (CSF1R), Ret and Yes. It shows ~100-fold selectivity for Chk1 than Chk2. Phase 1.
Y-27632 2HCl

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with K_i of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Alisertib (MLN8237)

Alisertib (MLN8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM in a cell-free assay. It has >200-fold higher selectivity for Aurora A than Aurora B. Phase 3.

Features:First orally available inhibitor of Aurora A.

Choose Your Country or Region

By Signaling Pathways

By product type

AZD7762

Cited by 55 Publications

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD7762 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Related Chk Products

Choose Your Country or Region

By Signaling Pathways

By product type

AZD7762

Cited by 55 Publications

Purity & Quality Control

Choose Selective Chk Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download AZD7762 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

Chk Signaling Pathway Map

Chk Inhibitors with Unique Features

Related Chk Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)